Pier Paolo Pandolfi

List of Publications by Year
in descending order

355	81,842	384 131	352 278
papers	citations	h-index	g-index

373	373	373	69905
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The HECT family of E3 ubiquitin ligases and PTEN. Seminars in Cancer Biology, 2022, 85, 43-51.	9.8	12
2	Two Different Therapeutic Approaches for SARS-CoV-2 in hiPSCs-Derived Lung Organoids. Cells, 2022, 11, 1235.	4.3	24
3	Skp2 dictates cell cycle-dependent metabolic oscillation between glycolysis and TCA cycle. Cell Research, 2021, 31, 80-93.	12.3	55
4	A focus on the spread of the delta variant of SARS-CoV-2 in India. Indian Journal of Medical Research, 2021, 153, 537.	1.1	42
5	Dual DNA and protein tagging of open chromatin unveils dynamics of epigenomic landscapes in leukemia. Nature Methods, 2021, 18, 293-302.	19.6	9
6	Inhibition of HECT E3 ligases as potential therapy for COVID-19. Cell Death and Disease, 2021, 12, 310.	6.5	36
7	COVID-19 Monitoring System using Social Distancing and Face Mask Detection on Surveillance video datasets. , 2021, , .		37
8	Copper Promotes Tumorigenesis by Activating the PDK1â€AKT Oncogenic Pathway in a Copper Transporter 1 Dependent Manner. Advanced Science, 2021, 8, e2004303.	12.3	81
9	Peptide Platform as a Powerful Tool in the Fight against COVID-19. Viruses, 2021, 13, 1667.	3.5	11
10	Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced Potency and Resistance to Escape Mutations. Journal of Molecular Biology, 2021, 433, 167177.	4.3	33
11	Pseudogenes as Competitive Endogenous RNAs: Target Prediction and Validation. Methods in Molecular Biology, 2021, 2324, 115-129.	1.4	0
12	In Vivo Silencing/Overexpression of lncRNAs by CRISPR/Cas System. Methods in Molecular Biology, 2021, 2348, 205-220.	1.4	3
13	Optimized RNA-targeting CRISPR/Cas13d technology outperforms shRNA in identifying functional circRNAs. Genome Biology, 2021, 22, 41.	9.1	94
14	Genetic fusions favor tumorigenesis through degron loss in oncogenes. Nature Communications, 2021, 12, 6704.	13.2	19
15	WWP1 inactivation enhances efficacy of PI3K inhibitors while suppressing their toxicities in breast cancer models. Journal of Clinical Investigation, 2021, 131, .	6.7	13
16	PTEN Mouse Models of Cancer Initiation and Progression. Cold Spring Harbor Perspectives in Medicine, 2020, 10, a037283.	6.3	15
17	WWP1 germline variants are associated with normocephalic autism spectrum disorder. Cell Death and Disease, 2020, 11, 529.	6.5	5
18	A somatic evolutionary model of the dynamics of aneuploid cells during hematopoietic reconstitution. Scientific Reports, 2020, 10, 12198.	3.5	0

#	Article	IF	Citations
19	The Tug1 lncRNA locus is essential for male fertility. Genome Biology, 2020, 21, 237.	9.1	71
20	Development of the Proximal-Anterior Skeletal Elements in the Mouse Hindlimb Is Regulated by a Transcriptional and Signaling Network Controlled by Sall4. Genetics, 2020, 215, 129-141.	2.9	10
21	WWP1 Gain-of-Function Inactivation of PTEN in Cancer Predisposition. New England Journal of Medicine, 2020, 382, 2103-2116.	30.7	56
22	PTENP1 is a ceRNA for PTEN: itâ€™s CRISPR clear. Journal of Hematology and Oncology, 2020, 13, 73.	17.8	14
23	Virus against virus: a potential treatment for 2019-nCov (SARS-CoV-2) and other RNA viruses. Cell Research, 2020, 30, 189-190.	12.3	150
24	LATS suppresses mTORC1 activity to directly coordinate Hippo and mTORC1 pathways in growth control. Nature Cell Biology, 2020, 22, 246-256.	10.1	68
25	Aberrant rRNA 2'-O-Methylation Causes Bone Marrow Failure and Defective Immune Function. Blood, 2020, 136, 11-12.	1.4	1
26	Interplay between c-Src and the APC/C co-activator Cdh1 regulates mammary tumorigenesis. Nature Communications, 2019, 10, 3716.	13.2	21
27	Epigenetic loss of RNA-methyltransferase NSUN5 in glioma targets ribosomes to drive a stress adaptive translational program. Acta Neuropathologica, 2019, 138, 1053-1074.	8.0	121
28	The Interplay Between the Genetic and Immune Landscapes of AML: Mechanisms and Implications for Risk Stratification and Therapy. Frontiers in Oncology, 2019, 9, 1162.	3.0	25
29	Abi1 loss drives prostate tumorigenesis through activation of EMT and non-canonical WNT signaling. Cell Communication and Signaling, 2019, 17, 120.	6.8	52
30	AKT methylation by SETDB1 promotes AKT kinase activity and oncogenic functions. Nature Cell Biology, 2019, 21, 226-237.	10.1	115
31	Intragenic antagonistic roles of protein and circRNA in tumorigenesis. Cell Research, 2019, 29, 628-640.	12.3	130
32	PTEN Methylation by NSD2 Controls Cellular Sensitivity to DNA Damage. Cancer Discovery, 2019, 9, 1306-1323.	14.3	62
33	Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathway. Science, 2019, 364, .	13.9	211
34	The PTENâ€“PI3K Axis in Cancer. Biomolecules, 2019, 9, 153.	4.2	199
35	Vulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapy. Cell Research, 2019, 29, 446-459.	12.3	34
36	miR-96-5p targets PTEN expression affecting radio-chemosensitivity of HNSCC cells. Journal of Experimental and Clinical Cancer Research, 2019, 38, 141.	9.0	65

#	Article	IF	Citations
37	PTEN self-regulates through USP11 via the PI3K-FOXO pathway to stabilize tumor suppression. Nature Communications, 2019, 10, 636.	13.2	55
38	Germline NPM1 mutations lead to altered rRNA 2â€²-O-methylation and cause dyskeratosis congenita. Nature Genetics, 2019, 51, 1518-1529.	20.4	90
39	SPOP Promotes Nanog Destruction to Suppress Stem Cell Traits and Prostate Cancer Progression. Developmental Cell, 2019, 48, 329-344.e5.	7.1	56
40	An Integrated Genome-wide CRISPRa Approach to Functionalize lncRNAs in Drug Resistance. Cell, 2018, 173, 649-664.e20.	28.1	248
41	Deregulated PP1Î± phosphatase activity towards MAPK activation is antagonized by a tumor suppressive failsafe mechanism. Nature Communications, 2018, 9, 159.	13.2	40
42	An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer. Nature Genetics, 2018, 50, 206-218.	20.4	240
43	Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms. Nature Medicine, 2018, 24, 165-175.	30.5	148
44	A non-cell-autonomous role for Pml in the maintenance of leukemia from the niche. Nature Communications, 2018, 9, 66.	13.2	25
45	Molecular Genetics of APL. , 2018, , 41-53.		1
46	The p85 isoform of the kinase S6K1 functions as a secreted oncoprotein to facilitate cell migration and tumor growth. Science Signaling, 2018, 11, .	5.2	10
47	ZBTB7A governs estrogen receptor alpha expression in breast cancer. Journal of Molecular Cell Biology, 2018, 10, 273-284.	3.4	17
48	Preclinical and Coclinical Studies in Prostate Cancer. Cold Spring Harbor Perspectives in Medicine, 2018, 8, a030544.	6.3	3
49	The Mouse Hospital and Its Integration in Ultra-Precision Approaches to Cancer Care. Frontiers in Oncology, 2018, 8, 340.	3.0	20
50	Loss of LDAH associated with prostate cancer and hearing loss. Human Molecular Genetics, 2018, 27, 4194-4203.	3.0	14
51	The functions and regulation of the PTEN tumour suppressor: new modes and prospects. Nature Reviews Molecular Cell Biology, 2018, 19, 547-562.	37.5	609
52	Inactivation of PBX3 and HOXA9 by down-regulating H3K79 methylation represses NPM1-mutated leukemic cell survival. Theranostics, 2018, 8, 4359-4371.	9.9	29
53	Compound haploinsufficiency of Dok2 and Dusp4 promotes lung tumorigenesis. Journal of Clinical Investigation, 2018, 129, 215-222.	6.7	18
54	Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity. Cancer Discovery, 2017, 7, 750-765.	14.3	115

#	Article	IF	Citations
55	MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia. Blood, 2017, 129, 1791-1801.	1.4	134
56	The APC/C E3 Ligase Complex Activator FZR1 Restricts BRAF Oncogenic Function. Cancer Discovery, 2017, 7, 424-441.	14.3	63
57	Nanoformulation of Olaparib Amplifies PARP Inhibition and Sensitizes PTEN/TP53-Deficient Prostate Cancer to Radiation. Molecular Cancer Therapeutics, 2017, 16, 1279-1289.	3.7	39
58	Persistent Immune Stimulation Exacerbates Genetically Driven Myeloproliferative Disorders via Stromal Remodeling. Cancer Research, 2017, 77, 3685-3699.	0.9	29
59	SPAR, a lncRNA encoded mTORC1 inhibitor. Cell Cycle, 2017, 16, 815-816.	2.8	22
60	The Epitranscriptome of Noncoding RNAs in Cancer. Cancer Discovery, 2017, 7, 359-368.	14.3	134
61	Regulation of NF-ÎºB by PML and PML-RARÎ±. Scientific Reports, 2017, 7, 44539.	3.5	19
62	mTORC1 and muscle regeneration are regulated by the LINC00961-encoded SPAR polypeptide. Nature, 2017, 541, 228-232.	36.3	527
63	Identification of competing endogenous RNAs of the tumor suppressor gene PTEN: A probabilistic approach. Scientific Reports, 2017, 7, 7755.	3.5	19
64	Acute Promyelocytic Leukemia: A Paradigm for Oncoprotein-Targeted Cure. Cancer Cell, 2017, 32, 552-560.	16.9	231
65	MCM7and its hosted miR-25, 93 and 106b cluster elicit YAP/TAZ oncogenic activity in lung cancer. Carcinogenesis, 2017, 38, 64-75.	2.8	53
66	A circular twist on microRNA regulation. Cell Research, 2017, 27, 1401-1402.	12.3	49
67	The RNA-binding protein ESRP1 promotes human colorectal cancer progression. Oncotarget, 2017, 8, 10007-10024.	1.8	60
68	Therapeutic inhibition of USP7-PTEN network in chronic lymphocytic leukemia: a strategy to overcome TP53 mutated/deleted clones. Oncotarget, 2017, 8, 35508-35522.	1.8	63
69	Dok-1 negatively regulates platelet integrin Î±IIbÎ²3 outside-in signalling and inhibits thrombosis in mice. Thrombosis and Haemostasis, 2016, 115, 969-978.	3.5	9
70	The Csk-Associated Adaptor PAG Inhibits Effector T Cell Activation in Cooperation with Phosphatase PTPN22 and Dok Adaptors. Cell Reports, 2016, 17, 2776-2788.	6.4	43
71	Oncogenic Role of Fusion-circRNAs Derived from Cancer-Associated Chromosomal Translocations. Cell, 2016, 165, 289-302.	28.1	589
72	Stress from Nucleotide Depletion Activates the Transcriptional Regulator HEXIM1 to Suppress Melanoma. Molecular Cell, 2016, 62, 34-46.	9.7	79

#	Article	IF	Citations
73	Dok1 and Dok2 Proteins Regulate Cell Cycle in Hematopoietic Stem and Progenitor Cells. Journal of Immunology, 2016, 196, 4110-4121.	0.8	14
74	Oncogenic Role of Fusion-circRNAs Derived from Cancer-Associated Chromosomal Translocations. Cell, 2016, 166, 1055-1056.	28.1	184
75	PHD3 Loss in Cancer Enables Metabolic Reliance on Fatty Acid Oxidation via Deactivation of ACC2. Molecular Cell, 2016, 63, 1006-1020.	9.7	126
76	The pleiotropic role of non-coding genes in development and cancer. Current Opinion in Cell Biology, 2016, 43, 104-113.	5.6	21
77	Posttranscriptional Regulation of PTEN by Competing Endogenous RNAs. Methods in Molecular Biology, 2016, 1388, 139-154.	1.4	1
78	Modeling Cancer-Associated Mutations of PTEN in Mice. Methods in Molecular Biology, 2016, 1388, 289-306.	1.4	1
79	Phosphatase-Independent Functions of the Tumor Suppressor PTEN. , 2016, , 247-260.		4
80	PML/RARa inhibits PTEN expression in hematopoietic cells by competing with PU.1 transcriptional activity. Oncotarget, 2016, 7, 66386-66397.	1.8	19
81	Endosome and INPP4B. Oncotarget, 2016, 7, 5-6.	1.8	18
82	Alterations of tumor microenvironment by carbon monoxide impedes lung cancer growth. Oncotarget, 2016, 7, 23919-23932.	1.8	40
83	Suppression of T-cell lymphomagenesis in mice requires PTEN phosphatase activity. Blood, 2015, 125, 852-855.	1.4	12
84	LRF maintains genome integrity by regulating the non-homologous end joining pathway of DNA repair. Nature Communications, 2015, 6, 8325.	13.2	18
85	The Promyelocytic Leukemia Protein Is Upregulated in Conditions of Obesity and Liver Steatosis. International Journal of Biological Sciences, 2015, 11, 629-632.	6.4	11
86	Pseudogenes in Human Cancer. Frontiers in Medicine, 2015, 2, 68.	2.7	96
87	Intravital imaging reveals p53-dependent cancer cell death induced by phototherapy via calcium signaling. Oncotarget, 2015, 6, 1435-1445.	1.8	86
88	ZBTB7A Suppresses Melanoma Metastasis by Transcriptionally Repressing MCAM. Molecular Cancer Research, 2015, 13, 1206-1217.	3.5	44
89	In Vivo Role of INPP4B in Tumor and Metastasis Suppression through Regulation of PI3Kâ€“AKT Signaling at Endosomes. Cancer Discovery, 2015, 5, 740-751.	14.3	89
90	Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis. Cancer Discovery, 2015, 5, 550-563.	14.3	25

#	Article	IF	Citations
91	PTEN ceRNA networks in human cancer. Methods, 2015, 77-78, 41-50.	3.9	123
92	BCR-ABL inactivates cytosolic PTEN through Casein Kinase II mediated tail phosphorylation. Cell Cycle, 2015, 14, 973-979.	2.8	26
93	p53 at the endoplasmic reticulum regulates apoptosis in a Ca ²⁺ -dependent manner. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 1779-1784.	7.6	257
94	PTEN Is a Negative Regulator of NK Cell Cytolytic Function. Journal of Immunology, 2015, 194, 1832-1840.	0.8	37
95	Distinct germline progenitor subsets defined through Tsc2â€“ <scp>mTORC</scp> 1 signaling. EMBO Reports, 2015, 16, 467-480.	4.6	58
96	A Genetic Platform to Model Sarcomagenesis from Primary Adult Mesenchymal Stem Cells. Cancer Discovery, 2015, 5, 396-409.	14.3	24
97	Causality and Chance in the Development of Cancer. New England Journal of Medicine, 2015, 373, 84-88.	30.7	45
98	Mouse hospital and co-clinical trial projectâ€"from bench to bedside. Nature Reviews Clinical Oncology, 2015, 12, 491-498.	27.9	112
99	Morgana acts as an oncosuppressor in chronic myeloid leukemia. Blood, 2015, 125, 2245-2253.	1.4	20
100	The BRAF Pseudogene Functions as a Competitive Endogenous RNA and Induces Lymphoma InÂVivo. Cell, 2015, 161, 319-332.	28.1	300
101	Active Pin1 is a key target of all-trans retinoic acid in acute promyelocytic leukemia and breast cancer. Nature Medicine, 2015, 21, 457-466.	30.5	232
102	Causality and Chance in the Development of Cancer. New England Journal of Medicine, 2015, 373, 1578-1579.	30.7	4
103	The PTEN Tumor Suppressor Forms Homodimers in Solution. Structure, 2015, 23, 1952-1957.	3.4	31
104	PTEN mediates Notch-dependent stalk cell arrest in angiogenesis. Nature Communications, 2015, 6, 7935.	13.2	88
105	SPOP Promotes Ubiquitination and Degradation of the ERG Oncoprotein to Suppress Prostate Cancer Progression. Molecular Cell, 2015, 59, 917-930.	9.7	175
106	Single-Cell Genomics Unveils Critical Regulators of Th17 Cell Pathogenicity. Cell, 2015, 163, 1400-1412.	28.1	523
107	A co-clinical platform to accelerate cancer treatment optimization. Trends in Molecular Medicine, 2015, 21, 1-5.	7.2	34
108	Loss of Wave1 gene defines a subtype of lethal prostate cancer. Oncotarget, 2015, 6, 12383-12391.	1.8	10

#	Article	IF	Citations
109	Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model. Oncotarget, 2015, 6, 42445-42467.	1.8	42
110	Establishment of a Humanized APL Model via the Transplantation of PML-RARA-Transduced Human Common Myeloid Progenitors into Immunodeficient Mice. PLoS ONE, 2014, 9, e111082.	2.4	9
111	miR-22 in tumorigenesis. Cell Cycle, 2014, 13, 11-12.	2.8	27
112	Aberrant ceRNA activity drives lung cancer. Cell Research, 2014, 24, 259-260.	12.3	42
113	Tumor microenvironment revisited. EMBO Reports, 2014, 15, 458-459.	4.6	10
114	Of Model Pets and Cancer Models: An Introduction to Mouse Models of Cancer. Cold Spring Harbor Protocols, 2014, 2014, pdb.top069757.	0.3	13
115	Enhancing Chemotherapy Efficacy in Pten -Deficient Prostate Tumors by Activating the Senescence-Associated Antitumor Immunity. Cell Reports, 2014, 9, 75-89.	6.4	333
116	A Unified Nomenclature and Amino Acid Numbering for Human PTEN. Science Signaling, 2014, 7, pe15.	5.2	51
117	<scp>HIF</scp> factors cooperate with <scp>PML</scp>â€<scp>RAR</scp>Î± to promote acute promyelocytic leukemia progression and relapse. EMBO Molecular Medicine, 2014, 6, 640-650.	6.9	37
118	Morgana acts as a protoâ€oncogene through inhibition of a <scp>ROCKâ€“PTEN</scp> pathway. Journal of Pathology, 2014, 234, 152-163.	4.5	22
119	MicroRNAs in the pathogenesis of myelodysplastic syndromes and myeloid leukaemia. Current Opinion in Hematology, 2014, 21, 276-282.	2.6	11
120	A Dialog on the First 20 Years of PML Research and the Next 20 Ahead. Frontiers in Oncology, 2014, 4, 23.	3.0	11
121	Utility of LRF/Pokemon and NOTCH1 Protein Expression in the Distinction Between Nodular Lymphocyte-Predominant Hodgkin Lymphoma and Classical Hodgkin Lymphoma. International Journal of Surgical Pathology, 2014, 22, 6-11.	0.9	7
122	NPMc+ cooperates with Flt3/ITD mutations to cause acute leukemia recapitulating human disease. Experimental Hematology, 2014, 42, 101-113.e5.	0.5	32
123	Cell-cycle-regulated activation of Akt kinase by phosphorylation at its carboxyl terminus. Nature, 2014, 508, 541-545.	36.3	297
124	Cancer-Associated PTEN Mutants Act in a Dominant-Negative Manner to Suppress PTEN Protein Function. Cell, 2014, 157, 595-610.	28.1	236
125	The multilayered complexity of ceRNA crosstalk and competition. Nature, 2014, 505, 344-352.	36.3	3,349
126	Role of BRAFV600E in the First Preclinical Model of Multifocal Infiltrating Myopericytoma Development and Microenvironment. Journal of the National Cancer Institute, 2014, 106, .	6.6	33

#	Article	IF	Citations
127	Dok1 and Dok2 proteins regulate natural killer cell development and function. EMBO Journal, 2014, 33, 1928-1940.	7.7	41
128	Characterization of Dual PTEN and p53-Targeting MicroRNAs Identifies MicroRNA-638/Dnm2 as a Two-Hit Oncogenic Locus. Cell Reports, 2014, 8, 714-722.	6.4	50
129	Targeting Lactate Dehydrogenase-A Inhibits Tumorigenesis and Tumor Progression in Mouse Models of Lung Cancer and Impacts Tumor-Initiating Cells. Cell Metabolism, 2014, 19, 795-809.	16.0	422
130	Proto-Oncogenic Role of Mutant IDH2 in Leukemia Initiation and Maintenance. Cell Stem Cell, 2014, 14, 329-341.	11.1	176
131	Bone Marrow Endosteal Mesenchymal Progenitors Depend on HIF Factors for Maintenance and Regulation of Hematopoiesis. Stem Cell Reports, 2014, 2, 794-809.	4.8	25
132	The Tumor Suppressor PML Specifically Accumulates at RPA/Rad51-Containing DNA Damage Repair Foci but Is Nonessential for DNA Damage-Induced Fibroblast Senescence. Molecular and Cellular Biology, 2014, 34, 1733-1746.	2.5	28
133	Vulnerabilities of PTENâ€“TP53-Deficient Prostate Cancers to Compound PARPâ€“PI3K Inhibition. Cancer Discovery, 2014, 4, 896-904.	14.3	88
134	Pseudogenes as Competitive Endogenous RNAs: Target Prediction and Validation. Methods in Molecular Biology, 2014, 1167, 199-212.	1.4	16
135	hnRNP K Overexpression Synergizes with Mutant NPM1 to Drive Acute Myeloid Leukemia Progression. Blood, 2014, 124, 2382-2382.	1.4	1
136	The BRAF Pseudogene Is a Proto-Oncogenic Competitive Endogenous RNA. Blood, 2014, 124, 263-263.	1.4	2
137	Role of aberrant PI3K pathway activation in gallbladder tumorigenesis. Oncotarget, 2014, 5, 894-900.	1.8	47
138	Hematological Malignancies and Premalignant Conditions. , 2014, , 467-486.		1
139	Abstract B06: Abi1 levels regulate prostate tumor progression in mice downstream from Pten inactivation. Molecular Cancer Research, 2014, , .	3.5	0
140	In Vivo Analysis of PML-RARA in a Humanized Mouse Model. Blood, 2014, 124, 1020-1020.	1.4	8
141	The Oncogenic MicroRNA miR-22 Targets the TET2 Tumor Suppressor to Promote Hematopoietic Stem Cell Self-Renewal and Transformation. Cell Stem Cell, 2013, 13, 87-101.	11.1	294
142	ceRNA Cross-Talk in Cancer: When ce-bling Rivalries Go Awry. Cancer Discovery, 2013, 3, 1113-1121.	14.3	770
143	Role of LRF/Pokemon in lineage fate decisions. Blood, 2013, 121, 2845-2853.	1.4	58
144	Characterization and Analysis of the Composition and Dynamics of the Mammalian Riboproteome. Cell Reports, 2013, 4, 1276-1287.	6.4	53

#	Article	IF	Citations
145	Dual Pten/Tp53 Suppression Promotes Sarcoma Progression by Activating Notch Signaling. American Journal of Pathology, 2013, 182, 2015-2027.	4.2	21
146	Cancer metabolism: fatty acid oxidation in the limelight. Nature Reviews Cancer, 2013, 13, 227-232.	27.8	1,016
147	Noncoding RNAs and Cancer. Cell, 2013, 153, 9-10.	28.1	41
148	From pseudo-ceRNAs to circ-ceRNAs: a tale of cross-talk and competition. Nature Structural and Molecular Biology, 2013, 20, 541-543.	8.1	114
149	Integrated transcriptional and competitive endogenous RNA networks are cross-regulated in permissive molecular environments. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 7154-7159.	7.6	312
150	The Mitochondrial Italian Human Proteome Project Initiative (mt-HPP). Molecular BioSystems, 2013, 9, 1984-92.	2.8	10
151	A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. Nature Genetics, 2013, 45, 747-755.	20.4	139
152	Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion. Nature Genetics, 2013, 45, 739-746.	20.4	138
153	MicroRNA-Antagonism Regulates Breast Cancer Stemness and Metastasis via TET-Family-Dependent Chromatin Remodeling. Cell, 2013, 154, 311-324.	28.1	420
154	Carbon Monoxide Expedites Metabolic Exhaustion to Inhibit Tumor Growth. Cancer Research, 2013, 73, 7009-7021.	0.9	309
155	Gata3 antagonizes cancer progression in Pten-deficient prostates. Human Molecular Genetics, 2013, 22, 2400-2410.	3.0	37
156	Synergy against PML-RARa: targeting transcription, proteolysis, differentiation, and self-renewal in acute promyelocytic leukemia. Journal of Experimental Medicine, 2013, 210, 2793-2802.	8.8	123
157	MUC1 Is a Potential Target for the Treatment of Acute Myeloid Leukemia Stem Cells. Cancer Research, 2013, 73, 5569-5579.	0.9	50
158	Effective Utilization and Appropriate Selection of Genetically Engineered Mouse Models for Translational Integration of Mouse and Human Trials. Cold Spring Harbor Protocols, 2013, 2013, pdb.top078774.	0.3	13
159	Pills of PTEN? In and out for tumor suppression. Cell Research, 2013, 23, 1155-1156.	12.3	10
160	The RNA Binding Protein ESRP1 Fine-Tunes the Expression of Pluripotency-Related Factors in Mouse Embryonic Stem Cells. PLoS ONE, 2013, 8, e72300.	2.4	40
161	DOK2 Inhibits EGFR-Mutated Lung Adenocarcinoma. PLoS ONE, 2013, 8, e79526.	2.4	12
162	The Lilliputians and the Giant: An Emerging Oncogenic microRNA Network that Suppresses the PTEN Tumor Suppressor In Vivo. MicroRNA (Shariqah, United Arab Emirates), 2013, 2, 127-136.	1.4	12

#	Article	IF	Citations
163	ceRNAs and ceRNA Networks in Normal and Malignant Hematopoiesis and Their Therapeutic Implications. Blood, 2013, 122, SCI-30-SCI-30.	1.4	0
164	Found in translation of mTOR signaling. Cell Research, 2012, 22, 1315-1318.	12.3	13
165	Compound In Vivo Inactivation of Pml and p53 Uncovers a Functional Interaction in Angiosarcoma Suppression. Genes and Cancer, 2012, 3, 599-603.	1.6	4
166	Stage-specific functions of leukemia/lymphoma-related factor (LRF) in the transcriptional control of osteoclast development. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2561-2566.	7.6	59
167	E6AP ubiquitin ligase regulates PML-induced senescence in Myc-driven lymphomagenesis. Blood, 2012, 120, 822-832.	1.4	51
168	A PMLâ€“PPAR-Î´ pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance. Nature Medicine, 2012, 18, 1350-1358.	30.5	636
169	Up-regulation of Translation Eukaryotic Initiation Factor 4E in Nucleophosmin 1 Haploinsufficient Cells Results in Changes in CCAAT Enhancer-binding Protein Î± Activity. Journal of Biological Chemistry, 2012, 287, 32728-32737.	3.5	17
170	Systemic Elevation of PTEN Induces a Tumor-Suppressive Metabolic State. Cell, 2012, 149, 49-62.	28.1	349
171	Acetylation-Dependent Regulation of Skp2 Function. Cell, 2012, 150, 179-193.	28.1	188
172	Akt Phosphorylates the Transcriptional Repressor Bmi1 to Block Its Effects on the Tumor-Suppressing Ink4a-Arf Locus. Science Signaling, 2012, 5, ra77.	5.2	53
173	Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer. Cancer Discovery, 2012, 2, 1048-1063.	14.3	397
174	A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature, 2012, 483, 613-617.	36.3	432
175	CIP2A Promotes Proliferation of Spermatogonial Progenitor Cells and Spermatogenesis in Mice. PLoS ONE, 2012, 7, e33209.	2.4	50
176	Promyelocytic Leukemia Zinc Finger Protein Activates GATA4 Transcription and Mediates Cardiac Hypertrophic Signaling from Angiotensin II Receptor 2. PLoS ONE, 2012, 7, e35632.	2.4	42
177	The functions and regulation of the PTEN tumour suppressor. Nature Reviews Molecular Cell Biology, 2012, 13, 283-296.	37.5	1,678
178	Dosage and tumour suppression. Journal of Pathology, 2012, 227, e1-e1.	4.5	0
179	Dokâ€1 overexpression promotes development of Î³Î´ natural killer <scp>T</scp> cells. European Journal of Immunology, 2012, 42, 2491-2504.	3.1	6
180	Translationâ€dependent mechanisms lead to PML upregulation and mediate oncogenic Kâ€RASâ€induced cellular senescence. EMBO Molecular Medicine, 2012, 4, 594-602.	6.9	29

#	Article	IF	Citations
181	â€œSnorkelingâ€•for missing players in cancer. Journal of Clinical Investigation, 2012, 122, 2765-2768.	6.7	17
182	Mouse Models of Human Cancer: Role in Preclinical Testing and Personalized Medicine. , 2012, , 569-589.		1
183	Targeting Leukemia Initiating Cells by MUC1-C Subunit Inhibition. Blood, 2012, 120, 3583-3583.	1.4	0
184	A PMLâ€“PPAR-Î´ Pathway for Fatty Acid Oxidation Regulates Hematopoietic Stem Cell Maintenance Through the Control of Asymmetric Division.. Blood, 2012, 120, 2327-2327.	1.4	6
185	A continuum model for tumour suppression. Nature, 2011, 476, 163-169.	36.3	440
186	Nuclear PTEN Regulates the APC-CDH1 Tumor-Suppressive Complex inÂa Phosphatase-Independent Manner. Cell, 2011, 144, 187-199.	28.1	340
187	A ceRNA Hypothesis: The Rosetta Stone of a Hidden RNA Language?. Cell, 2011, 146, 353-358.	28.1	6,173
188	Coding-Independent Regulation of the Tumor Suppressor PTEN by Competing Endogenous mRNAs. Cell, 2011, 147, 344-357.	28.1	951
189	InÂVivo Identification of Tumor- Suppressive PTEN ceRNAs in an Oncogenic BRAF-Induced Mouse Model of Melanoma. Cell, 2011, 147, 382-395.	28.1	616
190	Amplification of the Angiogenic Signal through the Activation of the TSC/mTOR/HIF Axis by the KSHV vGPCR in Kaposi's Sarcoma. PLoS ONE, 2011, 6, e19103.	2.4	59
191	Functional Connection between Rad51 and PML in Homology-Directed Repair. PLoS ONE, 2011, 6, e25814.	2.4	46
192	TSPYL5 suppresses p53 levels and function by physical interaction with USP7. Nature Cell Biology, 2011, 13, 102-108.	10.1	107
193	Pro-senescence therapy for cancer treatment. Nature Reviews Cancer, 2011, 11, 503-511.	27.8	404
194	SIRT3 Opposes Reprogramming of Cancer Cell Metabolism through HIF1Î± Destabilization. Cancer Cell, 2011, 19, 416-428.	16.9	705
195	Targeting of the Tumor Suppressor GRHL3 by a miR-21-Dependent Proto-Oncogenic Network Results in PTEN Loss and Tumorigenesis. Cancer Cell, 2011, 20, 635-648.	16.9	206
196	The nuclear bodies inside out: PML conquers the cytoplasm. Current Opinion in Cell Biology, 2011, 23, 360-366.	5.6	37
197	Haploâ€insufficiency: a driving force in cancer. Journal of Pathology, 2011, 223, 138-147.	4.5	109
198	Pml represses tumour progression through inhibition of mTOR. EMBO Molecular Medicine, 2011, 3, 249-257.	6.9	19

#	Article	IF	Citations
199	Cellular Senescence as a Possible Mechanism for Halting Progression of Keloid Lesions. Genes and Cancer, 2011, 2, 1061-1066.	1.6	25
200	Mitochondria associated membranes (MAMs) as critical hubs for apoptosis. Communicative and Integrative Biology, 2011, 4, 334-335.	1.5	43
201	Determining the contribution of NPM1 heterozygosity to NPM-ALK-induced lymphomagenesis. Laboratory Investigation, 2011, 91, 1298-1303.	4.0	8
202	The APL Paradigm and the â€œCo-Clinical Trialâ€•Project. Cancer Discovery, 2011, 1, 108-116.	14.3	119
203	Differential Expression of S6K2 Dictates Tissue-Specific Requirement for S6K1 in Mediating Aberrant mTORC1 Signaling and Tumorigenesis. Cancer Research, 2011, 71, 3669-3675.	0.9	19
204	Ubiquitination of K-Ras Enhances Activation and Facilitates Binding to Select Downstream Effectors. Science Signaling, 2011, 4, ra13.	5.2	155
205	PTEN Level in Tumor Suppression: How Much Is Too Little?. Cancer Research, 2011, 71, 629-633.	0.9	224
206	A Role for PML in Innate Immunity. Genes and Cancer, 2011, 2, 10-19.	1.6	51
207	Treatment with 5-Azacytidine Accelerates Acute Promyelocytic Leukemia Leukemogenesis in a Transgenic Mouse Model. Genes and Cancer, 2011, 2, 160-165.	1.6	2
208	Upregulation of eIF4E in Nucleophosmin 1 (NPM1) Haploinsufficient Cells Alters CCAAT Enhancer Binding Protein Alpha (C/EBPÎ±) Activity: Implications for MDS and AML. Blood, 2011, 118, 2432-2432.	1.4	0
209	The cytoplasmic NPM mutant induces myeloproliferation in a transgenic mouse model. Blood, 2010, 115, 3341-3345.	1.4	82
210	Generation of Functional Hepatocytes From Mouse Germ Line Cell-Derived Pluripotent Stem Cells In Vitro. Stem Cells and Development, 2010, 19, 1183-1194.	2.2	21
211	Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature, 2010, 464, 374-379.	36.3	361
212	A coding-independent function of gene and pseudogene mRNAs regulates tumour biology. Nature, 2010, 465, 1033-1038.	36.3	2,174
213	Deciphering the transcriptional complex critical for RhoA gene expression and cancer metastasis. Nature Cell Biology, 2010, 12, 457-467.	10.1	195
214	Identification of DOK genes as lung tumor suppressors. Nature Genetics, 2010, 42, 216-223.	20.4	108
215	Subtle variations in Pten dose determine cancer susceptibility. Nature Genetics, 2010, 42, 454-458.	20.4	512
216	The TLX1 oncogene drives aneuploidy in T cell transformation. Nature Medicine, 2010, 16, 1321-1327.	30.5	142

#	Article	IF	Citations
217	Development of Promyelocytic Zinc Finger and ThPOK-Expressing Innate Î³Î´ T Cells Is Controlled by Strength of TCR Signaling and Id3. Journal of Immunology, 2010, 184, 1268-1279.	0.8	143
218	eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 14134-14139.	7.6	460
219	CD8 T Cell-Intrinsic GITR Is Required for T Cell Clonal Expansion and Mouse Survival following Severe Influenza Infection. Journal of Immunology, 2010, 185, 7223-7234.	0.8	91
220	Identification of the miR-106b ~ 25 MicroRNA Cluster as a Proto-Oncogenic PTEN -Targeting Intron That Cooperates with Its Host Gene MCM7 in Transformation. Science Signaling, 2010, 3, ra29.	5.2	396
221	Faithfull Modeling of PTEN Loss Driven Diseases in the Mouse. Current Topics in Microbiology and Immunology, 2010, 347, 135-168.	0.0	29
222	Morgana/chp-1, a ROCK Inhibitor Involved in Centrosome Duplication and Tumorigenesis. Developmental Cell, 2010, 18, 486-495.	7.1	45
223	Plzf Regulates Germline Progenitor Self-Renewal by Opposing mTORC1. Cell, 2010, 142, 468-479.	28.1	241
224	A novel type of cellular senescence that can be enhanced in mouse models and human tumor xenografts to suppress prostate tumorigenesis. Journal of Clinical Investigation, 2010, 120, 681-693.	6.7	298
225	Cytoplasmic Nucleophosmin (NPMc+) Mutations and FMS-Like Tyrosine Kinase 3 (Flt3) Internal Tandem Duplication (ITD) Mutations Cooperate to Cause Leukemia In a Mouse Model. Blood, 2010, 116, 145-145.	1.4	1
226	Targeting Acute Myeloid Leukemia Stem Cells by MUC1-C Subunit Inhibition. Blood, 2010, 116, 848-848.	1.4	1
227	The Role of Nucleophosmin In Hematopoietic Stem Cells and the Pathogenesis of Myelodysplastic Syndrome. Blood, 2010, 116, 95-95.	1.4	5
228	Shape-shifting and tumor suppression by PLZF. Oncotarget, 2010, 1, 3-5.	1.8	7
229	BCL11B Mutations In T-Cell Acute Lymphoblastic Leukemia. Blood, 2010, 116, 471-471.	1.4	0
230	A Dual Proto-Oncogenic and Tumor Suppressive Role of LRF/POKEMON In Hemopoietic Malignancies through Control of Cell Fate Decision. Blood, 2010, 116, SCI-14-SCI-14.	1.4	0
231	TCR-inducible PLZF transcription factor required for innate phenotype of a subset of Î³Î´ T cells with restricted TCR diversity. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 12453-12458.	7.6	251
232	High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood, 2009, 114, 647-650.	1.4	418
233	Differential p53-Independent Outcomes of p19 ^{Arf} Loss in Oncogenesis. Science Signaling, 2009, 2, ra44.	5.2	60
234	Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. Journal of Clinical Investigation, 2009, 119, 1359-1372.	6.7	602

#	Article	IF	Citations
235	Evidence that Inositol Polyphosphate 4-Phosphatase Type II Is a Tumor Suppressor that Inhibits PI3K Signaling. Cancer Cell, 2009, 16, 115-125.	16.9	422
236	Promyelocytic Leukemia Zinc Finger Protein Regulates Interferon-Mediated Innate Immunity. Immunity, 2009, 30, 802-816.	14.1	89
237	ETS rearrangements and prostate cancer initiation. Nature, 2009, 457, E1-E1.	36.3	98
238	Phosphorylation-dependent regulation of cytosolic localization and oncogenic function of Skp2 by Akt/PKB. Nature Cell Biology, 2009, 11, 420-432.	10.1	217
239	Absence of nucleolar disruption after impairment of 40S ribosome biogenesis reveals an rpL11-translation-dependent mechanism of p53 induction. Nature Cell Biology, 2009, 11, 501-508.	10.1	305
240	Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nature Genetics, 2009, 41, 619-624.	20.4	602
241	LRF Is an Essential Downstream Target of GATA1 in Erythroid Development and Regulates BIM-Dependent Apoptosis. Developmental Cell, 2009, 17, 527-540.	7.1	101
242	A novel signaling network as a critical rheostat for the biology and maintenance of the normal stem cell and the cancer-initiating cell. Current Opinion in Genetics and Development, 2009, 19, 51-59.	3.4	47
243	Differential Requirement of mTOR in Postmitotic Tissues and Tumorigenesis. Science Signaling, 2009, 2, ra2.	5.2	64
244	Nucleophosmin-1 Interacts with CCAAT Enhancer Binding Protein Alpha (C/EBPÎ±) to Facilitate Granulocyte Maturation: Implications in MDS and AML.. Blood, 2009, 114, 2768-2768.	1.4	0
245	Akt-Mediated Phosphorylation of Bmi1 Regulates Its Chromatin Association and Growth Promoting Properties.. Blood, 2009, 114, 3605-3605.	1.4	0
246	Nucleophosmin Is Required for Macrophage Function and Maturation.. Blood, 2009, 114, 238-238.	1.4	1
247	PML targeting eradicates quiescent leukaemia-initiating cells. Nature, 2008, 453, 1072-1078.	36.3	524
248	The deubiquitinylation and localization of PTEN are regulated by a HAUSPâ€“PML network. Nature, 2008, 455, 813-817.	36.3	479
249	The BTBâ€“zinc finger transcriptional regulator PLZF controls the development of invariant natural killer T cell effector functions. Nature Immunology, 2008, 9, 1055-1064.	13.9	514
250	Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nature Medicine, 2008, 14, 1333-1342.	30.5	331
251	Tenets of PTEN Tumor Suppression. Cell, 2008, 133, 403-414.	28.1	962
252	SnapShot: PTEN Signaling Pathways. Cell, 2008, 133, 550-550.e1.	28.1	15

#	Article	IF	Citations
253	Acetylation of PML Is Involved in Histone Deacetylase Inhibitor-mediated Apoptosis. Journal of Biological Chemistry, 2008, 283, 24420-24425.	3.5	38
254	Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events. Genes and Development, 2008, 22, 2172-2177.	6.0	110
255	Nucleophosmin Serves as a Rate-Limiting Nuclear Export Chaperone for the Mammalian Ribosome. Molecular and Cellular Biology, 2008, 28, 7050-7065.	2.5	183
256	Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. Journal of Clinical Investigation, 2008, 118, 3065-74.	6.7	1,140
257	PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes and Development, 2008, 22, 436-448.	6.0	417
258	Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse. Blood, 2008, 111, 3859-3862.	1.4	120
259	The Proto-Oncogene LRF Is under Post-Transcriptional Control of MiR-20a: Implications for Senescence. PLoS ONE, 2008, 3, e2542.	2.4	80
260	Generation of a Factor Dependent Myeloid Cell Line from Nucleophosmin-1 Heterozygous (NPM-1+/â^') Mouse Bone Marrow as a Model for 5q- MDS. Blood, 2008, 112, 852-852.	1.4	0
261	PML-Retinoic Acid Receptor Î± Inhibits PML IV Enhancement of PU.1-Induced C/EBPÎµ Expression in Myeloid Differentiation. Molecular and Cellular Biology, 2007, 27, 5819-5834.	2.5	43
262	Repression of kit Expression by Plzf in Germ Cells. Molecular and Cellular Biology, 2007, 27, 6770-6781.	2.5	179
263	NEDD4-1 Is a Proto-Oncogenic Ubiquitin Ligase for PTEN. Cell, 2007, 128, 129-139.	28.1	637
264	Ubiquitination Regulates PTEN Nuclear Import and Tumor Suppression. Cell, 2007, 128, 141-156.	28.1	668
265	Essential Role for Nuclear PTEN in Maintaining Chromosomal Integrity. Cell, 2007, 128, 157-170.	28.1	894
266	The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nature Medicine, 2007, 13, 748-753.	30.5	277
267	Structure, dynamics and functions of promyelocytic leukaemia nuclear bodies. Nature Reviews Molecular Cell Biology, 2007, 8, 1006-1016.	37.5	823
268	Generation of functional multipotent adult stem cells from GPR125+ germline progenitors. Nature, 2007, 449, 346-350.	36.3	437
269	A CK2-Dependent Mechanism for Degradation of the PML Tumor Suppressor. Cell, 2006, 126, 269-283.	28.1	272
270	The Mechanisms of PML-Nuclear Body Formation. Molecular Cell, 2006, 24, 331-339.	9.7	463

#	Article	IF	Citations
271	Nucleophosmin and cancer. Nature Reviews Cancer, 2006, 6, 493-505.	27.8	748
272	Identification of a tumour suppressor network opposing nuclear Akt function. Nature, 2006, 441, 523-527.	36.3	363
273	PML inhibits HIF-1Î± translation and neoangiogenesis through repression of mTOR. Nature, 2006, 442, 779-785.	36.3	360
274	Dok-1 Independently Attenuates Ras/Mitogen-Activated Protein Kinase and Src/c-Myc Pathways To Inhibit Platelet-Derived Growth Factor-Induced Mitogenesis. Molecular and Cellular Biology, 2006, 26, 2479-2489.	2.5	51
275	p18 Ink4c and Pten Constrain a Positive Regulatory Loop between Cell Growth and Cell Cycle Control. Molecular and Cellular Biology, 2006, 26, 4564-4576.	2.5	43
276	A Novel Signal Transduction Cascade Involving Direct Physical Interaction of the Renin/Prorenin Receptor With the Transcription Factor Promyelocytic Zinc Finger Protein. Circulation Research, 2006, 99, 1355-1366.	6.5	289
277	The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice. Genes and Development, 2006, 20, 1569-1574.	6.0	231
278	In vivo analysis of the role of aberrant histone deacetylase recruitment and RARÎ± blockade in the pathogenesis of acute promyelocytic leukemia. Journal of Experimental Medicine, 2006, 203, 821-828.	8.8	42
279	Downstream of Tyrosine Kinases-1 and Src Homology 2-Containing Inositol 5â€²-Phosphatase Are Required for Regulation of CD4+CD25+ T Cell Development. Journal of Immunology, 2006, 176, 3958-3965.	0.8	57
280	Elucidating the Oncogenic Potential of NPMc+ In Vitro and In Vivo.. Blood, 2006, 108, 12-12.	1.4	6
281	LRF/Pokemon Plays a Pivotal Role in B Versus T Lymphoid Lineage Fate Decision at the Early Lymphoid Progenitor Stage by Opposing Notch1 Signaling.. Blood, 2006, 108, 778-778.	1.4	0
282	Stromal cellâ€“derived factor-1Î±/CXCL12â€“induced chemotaxis of T cells involves activation of the RasGAP-associated docking protein p62Dok-1. Blood, 2005, 105, 474-480.	1.4	57
283	The promyelocytic leukemia protein PML regulates c-Jun function in response to DNA damage. Blood, 2005, 105, 3686-3690.	1.4	48
284	The promyelocytic leukaemia protein tumour suppressor functions as a transcriptional regulator of p63. Oncogene, 2005, 24, 6982-6986.	5.9	40
285	Gli3 and Plzf cooperate in proximal limb patterning at early stages of limb development. Nature, 2005, 436, 277-281.	36.3	90
286	Role of nucleophosmin in embryonic development and tumorigenesis. Nature, 2005, 437, 147-153.	36.3	517
287	Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature, 2005, 436, 725-730.	36.3	1,788
288	Genetic analysis of Pten and Tsc2 functional interactions in the mouse reveals asymmetrical haploinsufficiency in tumor suppression. Genes and Development, 2005, 19, 1779-1786.	6.0	101

#	Article	IF	Citations
289	The Transcription Factor Pokemon: A New Key Player in Cancer Pathogenesis: Figure 1.. Cancer Research, 2005, 65, 8575-8578.	0.9	85
290	Role of the proto-oncogene Pokemon in cellular transformation and ARF repression. Nature, 2005, 433, 278-285.	36.3	465
291	Phosphorylation and Functional Inactivation of TSC2 by Erk. Cell, 2005, 121, 179-193.	28.1	1,153
292	The SUMO Pathway Is Essential for Nuclear Integrity and Chromosome Segregation in Mice. Developmental Cell, 2005, 9, 769-779.	7.1	462
293	Loss of the Tumor Suppressor PML in Human Cancers of Multiple Histologic Origins. Journal of the National Cancer Institute, 2004, 96, 269-279.	6.6	309
294	Role of Dok-1 and Dok-2 in Leukemia Suppression. Journal of Experimental Medicine, 2004, 200, 1689-1695.	8.8	83
295	PML regulates p53 stability by sequestering Mdm2 to the nucleolus. Nature Cell Biology, 2004, 6, 665-672.	10.1	306
296	Essential role of Plzf in maintenance of spermatogonial stem cells. Nature Genetics, 2004, 36, 653-659.	20.4	864
297	The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nature Medicine, 2004, 10, 484-486.	30.5	539
298	Myeloid leukemia with promyelocytic features in transgenic mice expressing hCG-NuMA-RARÎ±. Oncogene, 2004, 23, 665-678.	5.9	38
299	Aberrant mRNA translation in cancer pathogenesis: an old concept revisited comes finally of age. Oncogene, 2004, 23, 3134-3137.	5.9	64
300	Cytoplasmic PML function in TGF-Î² signalling. Nature, 2004, 431, 205-211.	36.3	294
301	Breast Cancer â€" Loss of PTEN Predicts Resistance to Treatment. New England Journal of Medicine, 2004, 351, 2337-2338.	30.7	152
302	PML Is a Direct p53 Target that Modulates p53 Effector Functions. Molecular Cell, 2004, 13, 523-535.	9.7	295
303	Mutations of the PML tumor suppressor gene in acute promyelocytic leukemia. Blood, 2004, 103, 2358-2362.	1.4	65
304	Activation of the P38 MAPK Pathway Results in Ubiquitin-Proteasome Degradation of the PML Tumor Suppressor Protein.. Blood, 2004, 104, 2553-2553.	1.4	0
305	Cytoplasmic PML Function in TGF-Î² Signaling.. Blood, 2004, 104, 481-481.	1.4	1
306	Role of PML and the PML-nuclear body in the control of programmed cell death. Oncogene, 2003, 22, 9048-9057.	5.9	176

#	Article	IF	Citations
307	Does the ribosome translate cancer?. Nature Reviews Cancer, 2003, 3, 179-192.	27.8	859
308	The Promyelocytic Leukemia Protein Protects p53 from Mdm2-mediated Inhibition and Degradation. Journal of Biological Chemistry, 2003, 278, 33134-33141.	3.5	123
309	Pten Dose Dictates Cancer Progression in the Prostate. PLoS Biology, 2003, 1, e59.	4.8	600
310	Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood, 2002, 100, 238-245.	1.4	390
311	Role of GITR in activation response of T lymphocytes. Blood, 2002, 100, 350-352.	1.4	173
312	The Role of PML in Tumor Suppression. Cell, 2002, 108, 165-170.	28.1	517
313	Plzf Mediates Transcriptional Repression of HoxD Gene Expression through Chromatin Remodeling. Developmental Cell, 2002, 3, 499-510.	7.1	162
314	Activation of Akt/Protein Kinase B Overcomes a G₂/M Cell Cycle Checkpoint Induced by DNA Damage. Molecular and Cellular Biology, 2002, 22, 7831-7841.	2.5	266
315	Regulation of Pax3 transcriptional activity by SUMO-1-modified PML. Oncogene, 2001, 20, 1-9.	5.9	103
316	Transcription therapy for cancer. Oncogene, 2001, 20, 3116-3127.	5.9	158
317	In vivo analysis of the molecular genetics of acute promyelocytic leukemia. Oncogene, 2001, 20, 5726-5735.	5.9	61
318	The theory of APL. Oncogene, 2001, 20, 7216-7222.	5.9	103
319	Mouse models for multistep tumorigenesis. Trends in Cell Biology, 2001, 11, S2-S9.	8.2	42
320	Role of Promyelocytic Leukemia (Pml) Sumolation in Nuclear Body Formation, 11s Proteasome Recruitment, and as2O3-Induced Pml or Pml/Retinoic Acid Receptor Î± Degradation. Journal of Experimental Medicine, 2001, 193, 1361-1372.	8.8	464
321	Phosphoinositide 3-Kinaseâ€“Dependent Membrane Recruitment of P62dok Is Essential for Its Negative Effect on Mitogen-Activated Protein (Map) Kinase Activation. Journal of Experimental Medicine, 2001, 194, 265-274.	8.8	63
322	P62dok, a Negative Regulator of Ras and Mitogen-Activated Protein Kinase (Mapk) Activity, Opposes Leukemogenesis by P210bcr-abl. Journal of Experimental Medicine, 2001, 194, 275-284.	8.8	103
323	Role of the Promyelocytic Leukemia Protein PML in the Interferon Sensitivity of Lymphocytic Choriomeningitis Virus. Journal of Virology, 2001, 75, 6204-6208.	3.4	77
324	Role of Promyelocytic Leukemia (Pml) Protein in Tumor Suppression. Journal of Experimental Medicine, 2001, 193, 521-530.	8.8	149

#	Article	IF	Citations
325	Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. Journal of Clinical Investigation, 2001, 108, 1321-1330.	6.7	238
326	The puzzling multiple lives of PML and its role in the genesis of cancer. BioEssays, 2000, 22, 827-835.	2.5	54
327	Plzf regulates limb and axial skeletal patterning. Nature Genetics, 2000, 25, 166-172.	20.4	270
328	Transcriptional regulation of cellular transformation. Nature Medicine, 2000, 6, 742-744.	30.5	24
329	The transcriptional role of PML and the nuclear body. Nature Cell Biology, 2000, 2, E85-E90.	10.1	520
330	PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature, 2000, 406, 207-210.	36.3	770
331	The function of PML in p53-dependent apoptosis. Nature Cell Biology, 2000, 2, 730-736.	10.1	434
332	Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nature Cell Biology, 2000, 2, 737-744.	10.1	2,516
333	Role of SUMO-1â€“modified PML in nuclear body formation. Blood, 2000, 95, 2748-2752.	1.4	498
334	Promyelocytic Leukemia Protein (Pml) and Daxx Participate in a Novel Nuclear Pathway for Apoptosis. Journal of Experimental Medicine, 2000, 191, 631-640.	8.8	210
335	Two Critical Hits for Promyelocytic Leukemia. Molecular Cell, 2000, 6, 1131-1141.	9.7	147
336	The Multiple Roles of PTEN in Tumor Suppression. Cell, 2000, 100, 387-390.	28.1	1,069
337	The puzzling multiple lives of PML and its role in the genesis of cancer. BioEssays, 2000, 22, 827-835.	2.5	2
338	A RA-dependent, tumour-growth suppressive transcription complex is the target of the PML-RARÎ± and T18 oncoproteins. Nature Genetics, 1999, 23, 287-295.	20.4	127
339	The p66shc adaptor protein controls oxidative stress response and life span in mammals. Nature, 1999, 402, 309-313.	36.3	1,628
340	In vivo analysis of the molecular pathogenesis of acute promyelocytic leukemia in the mouse and its therapeutic implications. Oncogene, 1999, 18, 5278-5292.	5.9	99
341	A role for PML and the nuclear body in genomic stability. Oncogene, 1999, 18, 7941-7947.	5.9	216
342	Impaired Fas Response and Autoimmunity in Pten+/ Mice. Science, 1999, 285, 2122-2125.	13.9	494

#	Article	IF	Citations
343	Targeted Disruption of CDK4 Delays Cell Cycle Entry with Enhanced p27^{Kip1} Activity. Molecular and Cellular Biology, 1999, 19, 7011-7019.	2.5	390
344	Pml is essential for multiple apoptotic pathways. Nature Genetics, 1998, 20, 266-272.	20.4	512
345	Distinct interactions of PML-RARÎ± and PLZF-RARÎ± with co-repressors determine differential responses to RA in APL. Nature Genetics, 1998, 18, 126-135.	20.4	569
346	Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nature Genetics, 1998, 19, 56-59.	20.4	1,378
347	Complete Remission after Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide. New England Journal of Medicine, 1998, 339, 1341-1348.	30.7	1,157
348	Molecular Cloning and Characterization of p56 Defines a New Family of RasGAP-binding Proteins. Journal of Biological Chemistry, 1998, 273, 4827-4830.	3.5	124
349	Acute Promyelocytic Leukemia as a Model for Cross-Talk Between Interferon and Retinoic Acid Pathways: From Molecular Biology to Clinical Applications. Leukemia and Lymphoma, 1998, 30, 11-22.	1.4	34
350	The chromosome make-up of mouse embryonic stem cells is predictive of somatic and germ cell chimaerism. Transgenic Research, 1997, 6, 321-328.	2.5	154
351	Gene rearrangements in the molecular pathogenesis of acute promyelocytic leukemia. Journal of Cellular Physiology, 1997, 173, 288-296.	4.2	37
352	Targeted disruption of the GATA3 gene causes severe abnormalities in the nervous system and in fetal liver haematopoiesis. Nature Genetics, 1995, 11, 40-44.	20.4	579
353	Lymphoid Malignancies. , 0, , .		4
354	Germline Modification Strategies. , 0, , .		3
355	Coding, or non-coding, that is the question. Cell Research, 0, , .	12.3	0